Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Buprenorphine-Naloxone Sublingual Spray vs Suboxone Film
NCT02477267Phase 1Completed
- Sponsor
- Insys Therapeutics
- Start
- Jun 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of buprenorphine + naloxone in opioid use disorder (OUD) (2 arms), sponsored by Insys Therapeutics. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Jun 2015; status: completed.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02477267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477267.